Ad
related to: immunology
Search results
Large Cap Trio for Value, Growth and Yield
MoneyShow via Yahoo Finance· 2 days agoWith a solid economy and a Fed still likely to cut interest rates this year, we believe the dividend yield of 2.6% and forward P/E ratio of 14 on our portfolio holdings are attractive, especially ...
Principal Securities Inc. Takes $3.63 Million Position in Johnson & Johnson (NYSE:JNJ)
ETF DAILY NEWS· 2 days agoPrincipal Securities Inc. acquired a new position in Johnson & Johnson (NYSE:JNJ – Free Report) in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional ...
OmniAb, Inc. (NASDAQ:OABI) Q1 2024 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 3 days agoOmniAb, Inc. (NASDAQ:OABI) Q1 2024 Earnings Call Transcript May 10, 2024 OmniAb, Inc. isn’t one of...
Nektar Therapeutics (NKTR) First Quarter 2024 Earnings Overview
GuruFocus.com via Yahoo Finance· 4 days agoThe biopharmaceutical company, known for its innovative approach in immunology and oncology, reported a net loss of $36.8 million, or $0.19 per share, aligning with analyst ...
UT Health San Antonio leading $11 million study of oral vaccine for chlamydia
San Antonio Current· 4 days agoGuangming Zhong made an accidental discovery that genital chlamydia in mice had spread to the...
Noxopharm scales up production of lupus drug SOF-SKN™ to GLP standards
Proactive Investors· 1 day agoNoxopharm Ltd (ASX:NOX, OTC:NOXOF) has reached a major drug development milestone in scaling up...
Tranq Has Been Found in the Drug Supply in Almost Every State. And Now, It’s Across the Pond.
Slate via Yahoo News· 3 days agoXylazine can bolster the effects of opioids. “It’s basically sought to increase the overall euphoria...
Kessler Investment Group LLC Reduces Holdings in Johnson & Johnson (NYSE:JNJ)
ETF DAILY NEWS· 3 days agoKessler Investment Group LLC reduced its stake in Johnson & Johnson (NYSE:JNJ – Free Report) by 98.8% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission ...
Replicate Bioscience Presents Positive Data from Phase 1 Trial and Preclinical Data with Novel...
WJTV Jackson· 4 days agoReplicate Bioscience, a clinical-stage company pioneering novel self-replicating RNA (srRNA) technology for use across a range of infectious disease, oncology, autoimmune disease indications ...
Q1 2024 Nektar Therapeutics Earnings Call
Thomson Reuters StreetEvents via Yahoo Finance· 5 days agoHoward? Howard Robin Thank you, Vivian, and thank you all for joining us today. We began 2024 with positive momentum as we continue to build a best-in-class pipeline focused on immunology ...